The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Sep. 22, 2009
Filed:
Dec. 09, 2003
John G. Gribben, Brookline, MA (US);
Gordon J. Freeman, Brookline, MA (US);
Lee M. Nadler, Newton, MA (US);
Paul Rennert, Holliston, MA (US);
Cindy L. Jellis, Londonderry, NH (US);
Edward Greenfield, Randolph, MA (US);
Gary S. Gray, Brookline, MA (US);
John G. Gribben, Brookline, MA (US);
Gordon J. Freeman, Brookline, MA (US);
Lee M. Nadler, Newton, MA (US);
Paul Rennert, Holliston, MA (US);
Cindy L. Jellis, Londonderry, NH (US);
Edward Greenfield, Randolph, MA (US);
Gary S. Gray, Brookline, MA (US);
Dana-Farber Cancer Institute, Inc., Boston, MA (US);
Genetics Institute, LLC, Cambridge, MA (US);
Abstract
Isolated ligands which bind a molecule expressed on the surface of T cells and induce antigen specific apoptosis in activated T cells are disclosed. Preferably, the T cell surface molecule is CTLA4 and the ligand is a monoclonal anti-CTLA4 antibody that binds to an epitope of CTLA4 distinct from the binding sites of B7-1 and B7-2. Upon binding of the antibody to CTLA4 on an activated T cell, in the presence of an antigenic signal, antigen specific apoptosis is induced. The invention also describes a novel natural CTLA4 ligand, distinct from B7-1 and B7-2, which mediates induction of apoptosis. Pharmaceutical compositions of anti-CTLA4 antibodies or other isolated CTLA4 ligands which can be administered to subjects to induce T cell apoptosis, thereby clonally deleting antigen specific T cells, such as alloreactive T cells in transplantation situations or autoreactive T cells in autoimmune disorders, are also disclosed. Methods for inducing T cell apoptosis in vitro with an anti-CTLA4 antibody or other ligand of the invention together with an antigen specific signal are also disclosed, e.g., for use in purging alloreactive T cells from donor bone marrow prior to bone marrow transplantation to inhibit graft versus host disease.